Name | Title | Contact Details |
---|---|---|
John MacDonald |
Vice President of Sales | Profile |
Christopher Horton |
Regional Vice President of Sales | Profile |
Rich Snider |
Vice President Advanced Products Group | Profile |
Dan O'Neill |
Director, R&D Quality Engineering | Profile |
Chris Heine |
Vice President, Research & Development | Profile |
Abiomed is a manufacturer of medical implant devices, including the AbioCor artificial heart and Impella. It is headquartered in Danvers, Massachusetts and has an additional office in Aachen, Germany. It has 500 employees.
Ceterix Orthopaedics is singularly focused on meniscal preservation and is dedicated to providing patients every opportunity to maintain the natural health and stability of their knee. The company develops tools that help surgeons repair many of the tears that currently remain untreated or are treated by meniscectomy (meniscus removal), a procedure associated with increased risk of arthritis or total knee replacement later in life. The Ceterix NovoStitch® Plus Meniscal Repair System provides surgeons with the unique ability to repair horizontal, radial, root and other complex tears. Based in Fremont, Calif., the company is backed by investors Novo Ventures, Versant Ventures and 5AM Ventures.
Alliance Surgical is a Olympia, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Ultradent Products, Inc., is a leading developer of high-tech dental materials, devices, and instruments worldwide. Ultradent`s mission is to improve the level of dental health care and to make dental procedures more predictable and efficient. Consistent with its mission, Ultradent works to improve the quality of life and the health of individuals through financial and charitable programs.
Acutus Medical is committed to pioneering a breakthrough technology to optimize the treatment strategies for complex cardiac arrhythmias by developing innovative, safe, efficacious, and cost-effective solutions for individuals suffering from these complex cardiac arrhythmias. Our mission is to develop and market a platform technology of safe, cost-effective and clinically advanced tools for the minimally invasive diagnosis (mapping) of complex arrhythmias (Atrial Fibrillation and Ventricular Tachycardia) that enable Physicians to optimize treatments and expand the ablation/therapeutic markets. In the pursuit of our mission, we will conduct all of our activities with the highest integrity and strive to become the world’s most valued company within the markets we serve to patients, customers, colleagues, investors, business partners, employees, and the communities in which we work and live.